October 28, 2010

Rigel Announces Presentations at Two Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:

Oppenheimer 21st Annual Healthcare Conference

New York, NY

November 3, 1:35 p.m. EDT

Speaker: Raul R. Rodriguez

Credit Suisse 19th Annual Healthcare Conference

Phoenix, AZ

November 11, 10:00 a.m. MST

Speaker: James M. Gower

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune disorders, as well as muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostimatinib (R788), an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.